Blood and clots can turn an upper endoscopy into a poor view of the very area the team needs to inspect. When a board stem uses 'improve diagnostic yield' to ask which medication can help clear the stomach before upper endoscopy, the expected answer is IV erythromycin. More precisely, its intended effect is improved gastric visualization; whether that reliably produces more definitive diagnoses or better patient outcomes is less certain. The useful learning point is to connect the answer to its purpose: improving the view, not stopping the hemorrhage.
Translate 'diagnostic yield' into the treatment goal
Erythromycin acts as a motilin-receptor agonist and increases gastric motility and emptying. Before endoscopy for upper gastrointestinal bleeding, the aim is to move retained blood and clot out of the stomach so the endoscopist can inspect the mucosa and identify a bleeding source more clearly.
A clearer view may make the first examination more informative. Guidelines note a possible reduction in repeat-look endoscopy, but evidence that improved visualization increases diagnostic success or patient-important outcomes remains limited. Erythromycin does not dissolve a clot, seal an ulcer, control variceal bleeding, reverse anticoagulation, or replace resuscitation and endoscopic hemostasis.
| If the treatment goal is… | Think… | The distinction that matters |
|---|---|---|
| Improve the view by promoting gastric emptying | IV erythromycin | A prokinetic adjunct before endoscopy |
| Alter gastric acidity or provide ulcer-related therapy | A proton pump inhibitor | A different mechanism; it does not clear retained blood by increasing motility |
| Reduce portal pressure in suspected variceal bleeding | A vasoactive agent such as octreotide | A separate treatment target; it is not the answer to a gastric-clearance question |
The macrolide label can distract candidates into thinking of erythromycin as an antimicrobial here. In this question, its relevant role is prokinetic—not treatment of a suspected infection.
Translate the timing into a board-ready answer
For the supplied question format, a concise response is: erythromycin 250 mg IV, infused before endoscopy, commonly 30–120 minutes beforehand. Timing windows vary across guidelines and local pathways; ACG material cites 20–90 minutes. In an exam, follow the window given in the stem. In clinical care, use the local protocol rather than treating one timing range as universal.
The indication also needs context. ACG guidance suggests erythromycin before endoscopy for hospitalized patients with upper GI bleeding. ESGE guidance recommends it for selected patients with clinically severe or ongoing active bleeding, where substantial blood or clot may obscure the view. The 2026 ESGE peptic-ulcer guideline carries forward the selective erythromycin recommendation and suggests IV metoclopramide as an alternative for selected patients if IV erythromycin is unavailable. That does not change the direct answer when a question specifically asks for erythromycin.
Evidence suggests erythromycin may improve visualization, but do not turn a better view into a promise of better survival. The certainty of evidence for important clinical outcomes remains limited. Say 'may improve visualization; guidelines note a possible reduction in repeat examination,' not 'prevents rebleeding' or 'reduces mortality.'
Keep the medication in its proper place in ED care
This is an adjunct, not a reason to delay stabilization or the endoscopy plan. For an unstable patient, resuscitation and coordination of definitive care take priority; erythromycin does not make ongoing hemorrhage safe to observe.
Before administration, consider the patient-specific risks. IV erythromycin can prolong the QT interval and has been associated with torsades de pointes, particularly in patients with known QT prolongation, electrolyte abnormalities, myocardial dysfunction, or interacting medications. Check the relevant history and medication list, and follow local guidance if risk is present. Do not let a memorized board answer override a contraindication or delay time-critical care.
A focused revision exercise: match the goal to the mechanism
Set a timer for six minutes and answer from memory before reopening your notes:
- Write the medication, route, common dose, and timing window used in the stem.
- Explain the mechanism in one chain: motilin activity → increased gastric emptying → less retained blood or clot → improved endoscopic view.
- In one sentence each, distinguish erythromycin from a PPI and from octreotide by the treatment goal each addresses.
- Name one safety concern and one outcome the evidence does not establish with confidence.
Then check your answers against a trusted guideline. Correct the missing link, not just the drug name. The next day, retrieve the answer from a differently worded prompt—for example, one asking why the endoscopist might have a better view after a pre-procedure medication. That tests whether you can reason from the clinical goal, not merely recognize a memorized timing phrase.
Practical takeaways
- For the question's 30–120-minute window, answer IV erythromycin; a common regimen is 250 mg by infusion.
- Its purpose is gastric emptying and improved visualization, not hemostasis or antimicrobial treatment.
- Separate the prokinetic question from acid suppression and portal-pressure treatment.
- Keep guideline timing, clinical indication, QT risk, and uncertainty about patient-important outcomes in view.
